v3.26.1
NET FINANCIAL RESULT (Details) - BRL (R$)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Financial expenses [Abstract]      
Interest on loans, financing and debentures R$ (5,679,047,000) R$ (4,453,739,000) R$ (3,636,730,000)
Premium expenses on early settlements 110,060,000
Amortization of transaction costs (101,926,000) (80,099,000) (67,353,000)
Interest expenses on lease liabilities (467,879,000) (451,148,000) (441,596,000)
Other (524,843,000) (556,917,000) (513,483,000)
Financial expenses (6,883,755,000) (5,541,903,000) (4,659,162,000)
Financial income [Abstract]      
Cash and cash equivalents and marketable securities 1,584,056,000 1,598,111,000 1,668,408,000
Other 182,570,000 139,323,000 157,241,000
Financial income 1,766,626,000 1,737,434,000 1,825,649,000
Results from derivative financial instruments [Abstract]      
Income 10,033,761,000 2,669,394,000 10,149,730,000
Expenses (2,705,077,000) (11,782,077,000) (4,623,016,000)
Derivative financial instruments, net 7,328,684,000 (9,112,683,000) 5,526,714,000
Monetary and exchange rate variations, net [Abstract]      
Exchange rate variations on loans, financing and debentures 8,384,101,000 (17,728,324,000) 4,185,675,000
Leases 304,959,000 (613,124,000) 180,112,000
Other assets and liabilities (1,138,450,000) 2,456,455,000 (1,278,060,000)
Monetary and exchange variations, net 7,550,610,000 (15,884,993,000) 3,087,727,000
Net financial result 9,762,165,000 (28,802,145,000) 5,780,928,000
Interest costs capitalised 274,731,000 959,968,000  
Transaction Costs for Loans and Financing   19,000  
Reclassification to biological assets 265,463,000 249,135,000 223,055
Disclosure of detailed information about biological assets [line items]      
Reclassification to biological assets R$ 265,463,000 R$ 249,135,000 R$ 223,055